Amylyx Pharmaceuticals, Inc. (AMLX)

In the past six months, Amylyx Pharmaceuticals' stock has been impacted by several events. In November 2025, the company reported its Q3 financial results and closed a public offering, securing approximately $191 million in net proceeds. In December 2025, Amylyx participated in Citi's 2025 Global Healthcare Conference and the 8th Annual Evercore Healthcare Conference. In March 2026, Amylyx reported its Q4 and Full Year 2025 financial results, completing recruitment for the pivotal Phase 3 LUCIDITY trial of avexitide in PBH. The company also presented at the Leerink Global Healthcare Conference and the TD Cowen 46th Annual Health Care Conference in March 2026. In April 2026, Amylyx Pharmaceuticals announced its participation in the 25th Annual Needham Virtual Healthcare Conference.

Information regarding specific demand seasonality for Amylyx Pharmaceuticals, Inc.'s products and services is not explicitly available. Demand for its products is likely driven more by disease prevalence, diagnosis rates, and treatment access rather than typical seasonal fluctuations.

Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company focused on therapies for neurodegenerative diseases and endocrine conditions. Its major products include AMX0035 (Relyvrio/Albrioza) for ALS, which is being withdrawn from the North American market after disappointing Phase 3 trial results, and Avexitide, an investigational GLP-1 receptor antagonist in Phase 3 trials for post-bariatric hypoglycemia (PBH) and studied in congenital hyperinsulinism. AMX0114 is an investigational therapy for ALS, and AMX0318 is a novel GLP-1 receptor antagonist for PBH and other rare diseases.

Amylyx Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts, and has an international presence through subsidiaries in Canada, the Netherlands, Ireland, the UK, Japan, Germany, and France. While AMX0035 received regulatory approvals in the U.S. and Canada, Amylyx aims to expand the availability of its therapies in international markets, including Europe and Asia.

Amylyx Pharmaceuticals' brand reputation has been shaped by the withdrawal of AMX0035 (Relyvrio/Albrioza) in April 2024 due to disappointing Phase 3 trial results. The company received praise for upholding its pre-approval commitment to withdraw the drug if it proved ineffective. The company emphasizes its mission to develop novel therapies for high unmet medical needs. Analyst sentiment towards AMLX is generally positive, with a consensus rating of "Moderate Buy" or "Strong Buy".

Amylyx Pharmaceuticals, Inc. has a diverse ownership structure, with 184 institutional owners and shareholders holding a total of 105,667,378 shares as of April 9, 2026. Major institutional shareholders include Fmr Llc, BlackRock, Inc., Perceptive Advisors Llc, and Vanguard Group Inc. FMR LLC held the largest institutional stake with 16.52 million shares as of December 31, 2025. Institutional investors collectively hold between approximately 46.54% and 84.19% of the company's stock, while insiders hold about 8.07%, and retail investors hold approximately 7.74%. Joseph Edelman owns the most shares among individual investors. In the past three months, insiders have sold more company stock than they have bought, with sales totaling $1,905,874.00 and no reported purchases.